A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate The Safety And Efficacy Of Ravulizumab In Complement-Inhibitor-Naïve Adult Patients With Generalized Myasthenia Gravis
Posted Date: Sep 24, 2019
- Investigator: Hani Kushlaf
- Specialties: Neurology, Neuromuscular Disorders
- Type of Study: Drug
This study involves an investigational drug called ravulizumab (referred to as “study drug”). This study drug is being developed to treat gMG by blocking complement activity. Complement activity is part of your immune system which fights against infections. In patients with gMG, abnormal complement activity is present, which causes damage to the structures in the body that are responsible for neuromuscular transmission. Ravulizumab is considered an experimental drug, which means it is not approved for use in gMG in any country at this time, outside of research studies like this one. The purpose of this study is to evaluate the safety and efficacy of ravulizumab intravenous (IV; in the vein) in subjects with gMG.
Criteria:
Null
Keywords:
Myasthenia Gravis, Ravulizumab, Neuromuscular
For More Information:
Lyssa Casale
513-558-4497
lyssa.casale@uc.edu